Zobrazeno 1 - 8
of 8
pro vyhledávání: ''
Autor:
John D. Hainsworth, David R. Spigel, Denise A. Yardley, Howard A. Burris, Patrick B. Murphy, F. Anthony Greco, C. Farley, Ruben A. Saez, John D. Zubkus
Publikováno v:
Journal of Thoracic Oncology. (12):1555-1560
Introduction Bevacizumab's role in the treatment of small cell lung cancer (SCLC) is unknown. A multicenter phase II trial with bevacizumab plus chemotherapy was conducted in patients with untreated extensive-stage SCLC. Methods Eligibility: no prior
Autor:
Brian Center, William Jeffrey Petty, Diandra Ayala, William H. Hinson, James Lovato, James Capellari, Timothy Oaks, Antonius A. Miller, Arthur William Blackstock
Publikováno v:
Journal of Thoracic Oncology. (1):69-74
Background Concurrent radiation and chemotherapy is the standard of care for good performance status patients with stage III non-small cell lung cancer. Locoregional control remains a significant factor relating to poor outcome. Preclinical and early
Autor:
Everett E. Vokes, Robert H. Christenson, Scott D. Jewell, Robert A. Kratzke, Martin J. Edelman, Xiaofei Wang, Lydia Hodgson
Publikováno v:
Journal of Thoracic Oncology. (11):1902-1906
Introduction Eicosanoids, including PGE-2 and 5-HETE, can increase levels of plasma vascular endothelial growth factor (VEGF). Overexpression of COX-2 or 5-LOX increases levels of PGE-2 and 5-HETE, respectively. Elevated levels of VEGF are common in
Publikováno v:
Journal of Thoracic Oncology. (11):1857-1864
Introduction For patients with stage III non-small cell lung cancer treated with induction chemotherapy (ICT), delayed initiation of subsequent radiotherapy (RT) may allow for repopulation in the interval between treatment modalities and during the e
Autor:
Yi Yeong Jeong, Young Sil Hwang, Jong Duk Lee, Ho Cheol Kim, Jeong-Hee Lee, Jong Sil Lee, Jung Wook Yang, Gyeong-Won Lee, Gyung Hyuck Ko, Se Il Go, Sukjoong Oh, Dong Chool Kim, Yu Ji Cho
Publikováno v:
Journal of Thoracic Oncology. (3):528-534
IntroductionHypoxia-inducible factor-1α (HIF-1α), which plays an essential role in the adaptive response of cells to hypoxia, is associated with aggressive tumor behavior. Furthermore, a relationship between excision repair cross-complementing 1 (E
Autor:
Bernhard Holzmann, Wolfram T. Knoefel, Joerg Theisen, Matthias Schauer, Helmut Friess, Matthias Peiper
Publikováno v:
Journal of Thoracic Oncology. (11):1849-1854
Introduction:Chemotherapy-associated mucositis often prevents completion of an entire chemotherapy cycle. The underlying pathophysiology of chemotherapy-associated mucositis has not been well established. The individual immunologic predisposition of
Autor:
Coleman K. Obasaju, Hak Choy, Edward B. Garon, Andrew Koustenis, Ramaswamy Govindan, Joseph Treat, Janak K. Choksi, David E. Gerber, Shaker R. Dakhil, Lee S. Schwartzberg, Guangbin Peng
Publikováno v:
Journal of Thoracic Oncology. (10):1308-1316
Introduction There is no consensus chemotherapy regimen with concurrent radiotherapy (RT) for inoperable stage IIIA/B non-small-cell lung cancer. This trial evaluated pemetrexed with carboplatin (PCb) or cisplatin (PC) with concurrent RT followed by
Autor:
David Pérol, Catherine Dubos, Christos Chouaid, G. Zalcman, O. Bylicki, Lionel Falchero, Fabien Vaylet, Isabelle Monnet, Jacky Crequit, Pauline Linard, Roman Corre, Celine Ferlay, Hervé Le Caer, Virginie Westeel, Pierre Fournel, Michel Poudenx, Armelle Lavolé, Alain Vergnenegre, Fabrice Barlesi, Maurice Pérol
Publikováno v:
Journal of Thoracic Oncology. (7):906-914
Introduction Maintenance therapy in advanced non–small-cell lung cancer (NSCLC) might lead to resistance to subsequent treatments. IFCT–GFPC 0502 study showed a progression-free survival (PFS) benefit with gemcitabine or erlotinib maintenance com